Gene III Biotechnology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Gene III Biotechnology Co., Ltd. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include GENEIII. The owner is based in Jiangsu Province.
7th Floor, Building 4, No.6 Xuzhuang Road, Xuanwu District, Nanjing City,
Jiangsu Province 211000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Gene III Biotechnology Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Gene III Biotechnology Co., Ltd. have?
Gene III Biotechnology Co., Ltd. has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Gene III Biotechnology Co., Ltd. file in?
Gene III Biotechnology Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Gene III Biotechnology Co., Ltd.'s most well-known trademarks?
Gene III Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as GENEIII. These are among 3 currently registered trademarks in the portfolio.
What is Gene III Biotechnology Co., Ltd.'s trademark registration success rate?
Gene III Biotechnology Co., Ltd. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.